Mesenchymal stem cells attenuate acute ischemia-reperfusion injury in a rat model

Lu,Weifeng; Si,Yi; Ding,Jianyong; Chen,Xiaoli; Zhang,Xiangman; Dong,Zhihui; Fu,Weiguo

doi:10.3892/etm.2015.2806

Mesenchymal stem cells attenuate acute ischemia-reperfusion injury in a rat model

Authors:
- Weifeng Lu
- Yi Si
- Jianyong Ding
- Xiaoli Chen
- Xiangman Zhang
- Zhihui Dong
- Weiguo Fu
View Affiliations

Affiliations: Department of Vascular Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, P.R. China, Department of Cardiovascular Surgery, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai 200032, P.R. China, Department of Thoracic Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, P.R. China, Cancer Research Center, Medical College of Xiamen University, Xiamen, Fujian 361004, P.R. China, Institute of Vascular Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, P.R. China
Published online on: October 15, 2015 https://doi.org/10.3892/etm.2015.2806
Pages: 2131-2137
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ischemia-reperfusion injury (IRI) following lung transplantation is associated with increased pulmonary inflammatory responses during reperfusion. Mesenchymal stem cells (MSCs) may be able to modulate inflammatory responses in IRI. The aim of the present study was to evaluate the beneficial effects of an intravenous infusion of bone marrow‑derived MSCs (BMSCs) in a rat model of pulmonary IRI. IRI was induced in male Lewis rats by 1‑h ischemia followed by 2‑h reperfusion. The rats received phosphate‑buffered saline (PBS) or BMSC infusion at the onset of reperfusion. Pulmonary injury was determined based on the mean blood oxygenation, lung edema and vascular permeability, and performing histopathological examination. Pulmonary inflammation was also evaluated through the examination of the levels of inflammatory cytokines. Compared with the PBS infusion, the BMSC infusion significantly preserved lung function, reduced lung edema and pulmonary microvascular permeability, and decreased the total injury score in rats with IRI. The mRNA levels of the pro‑inflammatory cytokines, tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑1β and IL‑6, were significantly reduced, while the expression of anti‑inflammatory cytokine IL‑10 was increased in the rats receiving BMSC infusion. The levels of cytokine‑induced neutrophil chemoattractant‑1, IL‑1β, and TNF‑α in bronchoalveolar lavage fluid were also markedly reduced following BMCS infusion. In conclusion, the present results suggested that BMSC infusion exerts protective effects against pulmonary IRI by alleviating IRI‑induced inflammation. These findings provide experimental evidence for the treatment of pulmonary IRI using BMSC cell therapy.

View Figures

View References

1	Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM and Hertz MI: International Society for Heart and Lung Transplantation: Registry of the international society for heart and lung transplantation: Twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant. 25:880–892. 2006. View Article : Google Scholar : PubMed/NCBI
2	Yang Z, Sharma AK, Linden J, Kron IL and Laubach VE: CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 137:695–702. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sharma AK, Laubach VE, Ramos SI, Zhao Y, Stukenborg G, Linden J, Kron IL and Yang Z: Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 139:474–482. 2010. View Article : Google Scholar : PubMed/NCBI
4	Anvari F, Sharma AK, Fernandez LG, Hranjec T, Ravid K, Kron IL and Laubach VE: Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 140:871–877. 2010. View Article : Google Scholar : PubMed/NCBI
5	Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga CH, Goss CH and Mulligan MS: Early tumor necrosis factor-alpha release from the pulmonary macrophage in lung ischemia reperfusion injury. J Thorac Cardiovasc Surg. 127:1502–1508. 2004. View Article : Google Scholar : PubMed/NCBI
6	Maxey TS, Enelow RI, Gaston B, Kron IL, Laubach VE and Doctor A: Tumor necrosis factor-alpha from resident lung cells is a key initiating factor in pulmonary ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 127:541–547. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ding JY, Tang L, Xu ST and Wang Q: Influence of pyrrolidine dithiocarbamate pretreatment on function of the transplanted rat lung. Zhong Guo Lin Chuang Yi Xue. 17:795–798. 2010.(In Chinese).
8	Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K, Tsuruyama T, Uemoto S and Kobayashi E: Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One. 6:e191952011. View Article : Google Scholar : PubMed/NCBI
9	Liu H, Liu S, Li Y, Wang X, Xue W, Ge G and Luo X: The Role of SDF-1-CXCR4/CXCR7 Axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS ONE. 7:e346082012. View Article : Google Scholar : PubMed/NCBI
10	Jiang H, Qu L, Li Y, Gu L, Shi Y, Zhang J, Zhu W and Li J: Bone marrow mesenchymal stem cells reduce intestinal ischemia/reperfusion injuries in rats. J Surg Res. 168:127–134. 2011. View Article : Google Scholar : PubMed/NCBI
11	Wang M, Tsai BM, Crisostomo PR and Meldrum DR: Pretreatment with adult progenitor cells improves recovery and decreases native myocardial proinflammatory signaling after ischemia. Shock. 25:454–459. 2006. View Article : Google Scholar : PubMed/NCBI
12	Dharmasaroja P: Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci. 16:12–20. 2009. View Article : Google Scholar : PubMed/NCBI
13	Tögel F, Hu Z, Weiss K, Isaac J, Lange C and Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 289:F31–F42. 2005. View Article : Google Scholar : PubMed/NCBI
14	Chen S, Chen L, Wu X, Lin J, Fang J, Chen X, Wei S, Xu J, Gao Q and Kang M: Ischemia postconditioning and mesenchymal stem cells engraftment synergistically attenuate ischemia reperfusion-induced lung injury in rats. J Surg Res. 178:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
15	Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, Chua S, Fu M, Ko SF, Leu S and Yip HK: Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med. 9:1182011. View Article : Google Scholar : PubMed/NCBI
16	Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 15:42–49. 2009. View Article : Google Scholar : PubMed/NCBI
17	Nauta AJ and Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506. 2007. View Article : Google Scholar : PubMed/NCBI
18	Rasmusson I: Immune modulation by mesenchymal stem cells. Exp Cell Res. 312:2169–2179. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K, Fujiwara M, Kitamura S, Nagaya N and Ikeda T: Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells. 26:2625–2633. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kabay B, Aytekin FO, Aydin C, Ozer A, Kabay N, Tekin K, Sungurtekin U, Erdem E and Ozden A: Interleukin-10 gene therapy attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion in a mouse model. Tohoku J Exp Med. 207:133–142. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ajuebor MN, Das AM, Virág L, Flower RJ, Szabó C and Perretti M: Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: Evidence for an inhibitory loop involving endogenous IL-10. J Immunol. 162:1685–1691. 1999.PubMed/NCBI
23	Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC and Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med. 182:1047–1057. 2010. View Article : Google Scholar : PubMed/NCBI